Vidiia provides AI-driven portable diagnostic devices that enable real-time virus testing and analysis, enhancing accessibility to molecular diagnostics. The platform's cloud services facilitate seamless data integration and expert guidance, ensuring effective implementation in diverse testing environments.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional molecular diagnostic testing often requires specialized laboratory equipment and trained personnel, limiting accessibility in resource-constrained settings or point-of-care applications. The complexity and cost of these tests can also delay diagnosis and treatment initiation.
Solution
Vidiia offers portable, AI-driven diagnostic devices that enable real-time molecular testing and analysis outside of traditional laboratory settings. The platform aims to increase accessibility to molecular diagnostics by providing affordable and user-friendly devices. Vidiia's cloud services facilitate data integration and provide access to expert guidance, ensuring effective implementation in diverse testing environments. The company's Assay Accelerator program offers tailored research frameworks to guide users through design, development, optimization, validation, adoption, and impact testing.
Target Audience
The primary target audience includes researchers and healthcare providers seeking to expand access to molecular diagnostics in point-of-care settings or resource-limited environments.
Features
- Portable diagnostic devices for on-site molecular testing
- AI-driven analysis for rapid results
- Cloud services for data integration and remote expert support
- Assay Accelerator program providing a structured research framework